Please assess the completion status of the following clinical trial:

Trial Title: How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult glaucoma patients who are taking drops: dor-tim and Latanoprost Ophthalmic Solution 0.005% (Lat) and come in for an appointment during the trial period~Exclusion Criteria:~* Patients who had an SLT or glaucoma procedure or surgery within 3 months of enrollment will be excluded. Other exclusion criteria include the logistical inability to follow up with the trial, the inability to relax eye muscles for an accurate tonometry measurement, and the inability to instill medications.~The final determination to be included in the study will be made by the Physician on the day of the appointment.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- full dose lat dor-tim; tim-brim-dor-bim (Type: ACTIVE_COMPARATOR): After baseline IOP measurements, subjects in this arm will use the full dose full dose latanoprost and dorzolamide-timolol in phase 2, and then timolol-brimonidine-dorzolamide-bimatoprost in phase 3.
- tim-brim-dor-bim; full dose lat dor-tim (Type: ACTIVE_COMPARATOR): After baseline IOP measurements, subjects in this arm will use timolol-brimonidine-dorzolamide-bimatoprost in phase 2, and then full dose latanoprost and dorzolamide-timolol in phase 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).